Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Accounts Payables (2017 - 2025)

Autolus Therapeutics' Accounts Payables history spans 9 years, with the latest figure at $3.1 million for Q4 2025.

  • For Q4 2025, Accounts Payables rose 56.58% year-over-year to $3.1 million; the TTM value through Dec 2025 reached $3.1 million, up 56.58%, while the annual FY2025 figure was $3.1 million, 56.58% up from the prior year.
  • Accounts Payables reached $3.1 million in Q4 2025 per AUTL's latest filing, down from $11.0 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $11.0 million in Q3 2025 to a low of $103000.0 in Q4 2023.
  • Average Accounts Payables over 5 years is $2.1 million, with a median of $1.1 million recorded in 2024.
  • Peak YoY movement for Accounts Payables: tumbled 80.95% in 2021, then skyrocketed 2293.83% in 2023.
  • A 5-year view of Accounts Payables shows it stood at $431000.0 in 2021, then increased by 23.2% to $531000.0 in 2022, then plummeted by 80.6% to $103000.0 in 2023, then surged by 1811.65% to $2.0 million in 2024, then surged by 56.58% to $3.1 million in 2025.
  • Per Business Quant, the three most recent readings for AUTL's Accounts Payables are $3.1 million (Q4 2025), $11.0 million (Q3 2025), and $5.4 million (Q2 2025).